How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel
Executive Summary
After well-publicized problems in Johnson & Johnson’s devices and consumer health divisions, in the words of a recent Deutsche Bank research note, “It’s pharmaceuticals’ time to shine.” Indeed, the diversified health care company expects to file 11 new drugs and over 31 line extensions by 2015. Though growth is now expected from J&J’s pharma business, less well understood is the role of biologics, both marketed and near to market, in driving that expansion and J&J’s increased focus on specialty products.
You may also be interested in...
Janssen R&D’s Immunology Unit Grounded In Translational Thinking
J&J finished pulling together its disparate R&D efforts under the Janssen name in December, with a distinctive translational thread running through the entire soup-to-nuts operation. The immunology unit showcases the firm’s success with this method – the understanding of a psoriasis mechanism gained in the clinic looped back to inform research on several next generation therapies and a very broad Remicade label.
Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel
The entire class of biologics has fallen under suspicion of worsening the very condition it is supposed to treat, and FDA has imposed clinical holds on ongoing trials.
Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel
The entire class of biologics has fallen under suspicion of worsening the very condition it is supposed to treat, and FDA has imposed clinical holds on ongoing trials.